Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes

Ildiko Lingvay, Philip Raskin, Lidia S. Szczepaniak

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: Hepatic steatosis occurs in up to 78% of patients with type 2 diabetes. Studies evaluating the effect of metformin on hepatic steatosis are conflicting. Insulin is believed to be detrimental due to its lipogenic effect. Since insulin-metformin combination is commonly used for the treatment of diabetes, it is important to assess the effect of this combined therapy on hepatic steatosis. We evaluated the change in hepatic steatosis following the initiation of insulin and metformin in patients with type 2 diabetes. Methods: Newly diagnosed treatment-naïve patients with type 2 diabetes had their hepatic triglyceride (TG) content measured by magnetic resonance spectroscopy at baseline and after 3 months of treatment with BiAsp 30 insulin, in combination with metformin. Insulin was administered twice daily and titrated to achieve normal capillary blood glucose levels. Metformin was titrated during the first month from 500 mg daily to 1000 mg bid. Results: The average hepatic TG content in 19 enrolled subjects was 11.83±7.61% (range, 0.93-23.16%) and correlated with body mass index (r=.567). Three months of treatment reduced hepatic steatosis by 45%, with 75% of the study subjects achieving a normal level. The change in hepatic TG content was partially explained by changes in HbA1c (P=.006) and cholesterol (P=.003) levels. Conclusions: The combined treatment with insulin and metformin significantly reduced hepatic steatosis in patients with newly diagnosed type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)137-142
Number of pages6
JournalJournal of Diabetes and its Complications
Volume21
Issue number3
DOIs
StatePublished - May 2007

Fingerprint

Metformin
Type 2 Diabetes Mellitus
Insulin
Liver
Triglycerides
Therapeutics
Blood Glucose
Body Mass Index
Magnetic Resonance Spectroscopy
Cholesterol

Keywords

  • Hepatic steatosis
  • Insulin treatment
  • Metformin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. / Lingvay, Ildiko; Raskin, Philip; Szczepaniak, Lidia S.

In: Journal of Diabetes and its Complications, Vol. 21, No. 3, 05.2007, p. 137-142.

Research output: Contribution to journalArticle

@article{c08d7139771241deaf2d0cc45e402aad,
title = "Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes",
abstract = "Objective: Hepatic steatosis occurs in up to 78{\%} of patients with type 2 diabetes. Studies evaluating the effect of metformin on hepatic steatosis are conflicting. Insulin is believed to be detrimental due to its lipogenic effect. Since insulin-metformin combination is commonly used for the treatment of diabetes, it is important to assess the effect of this combined therapy on hepatic steatosis. We evaluated the change in hepatic steatosis following the initiation of insulin and metformin in patients with type 2 diabetes. Methods: Newly diagnosed treatment-na{\"i}ve patients with type 2 diabetes had their hepatic triglyceride (TG) content measured by magnetic resonance spectroscopy at baseline and after 3 months of treatment with BiAsp 30 insulin, in combination with metformin. Insulin was administered twice daily and titrated to achieve normal capillary blood glucose levels. Metformin was titrated during the first month from 500 mg daily to 1000 mg bid. Results: The average hepatic TG content in 19 enrolled subjects was 11.83±7.61{\%} (range, 0.93-23.16{\%}) and correlated with body mass index (r=.567). Three months of treatment reduced hepatic steatosis by 45{\%}, with 75{\%} of the study subjects achieving a normal level. The change in hepatic TG content was partially explained by changes in HbA1c (P=.006) and cholesterol (P=.003) levels. Conclusions: The combined treatment with insulin and metformin significantly reduced hepatic steatosis in patients with newly diagnosed type 2 diabetes.",
keywords = "Hepatic steatosis, Insulin treatment, Metformin, Type 2 diabetes",
author = "Ildiko Lingvay and Philip Raskin and Szczepaniak, {Lidia S.}",
year = "2007",
month = "5",
doi = "10.1016/j.jdiacomp.2007.02.005",
language = "English (US)",
volume = "21",
pages = "137--142",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes

AU - Lingvay, Ildiko

AU - Raskin, Philip

AU - Szczepaniak, Lidia S.

PY - 2007/5

Y1 - 2007/5

N2 - Objective: Hepatic steatosis occurs in up to 78% of patients with type 2 diabetes. Studies evaluating the effect of metformin on hepatic steatosis are conflicting. Insulin is believed to be detrimental due to its lipogenic effect. Since insulin-metformin combination is commonly used for the treatment of diabetes, it is important to assess the effect of this combined therapy on hepatic steatosis. We evaluated the change in hepatic steatosis following the initiation of insulin and metformin in patients with type 2 diabetes. Methods: Newly diagnosed treatment-naïve patients with type 2 diabetes had their hepatic triglyceride (TG) content measured by magnetic resonance spectroscopy at baseline and after 3 months of treatment with BiAsp 30 insulin, in combination with metformin. Insulin was administered twice daily and titrated to achieve normal capillary blood glucose levels. Metformin was titrated during the first month from 500 mg daily to 1000 mg bid. Results: The average hepatic TG content in 19 enrolled subjects was 11.83±7.61% (range, 0.93-23.16%) and correlated with body mass index (r=.567). Three months of treatment reduced hepatic steatosis by 45%, with 75% of the study subjects achieving a normal level. The change in hepatic TG content was partially explained by changes in HbA1c (P=.006) and cholesterol (P=.003) levels. Conclusions: The combined treatment with insulin and metformin significantly reduced hepatic steatosis in patients with newly diagnosed type 2 diabetes.

AB - Objective: Hepatic steatosis occurs in up to 78% of patients with type 2 diabetes. Studies evaluating the effect of metformin on hepatic steatosis are conflicting. Insulin is believed to be detrimental due to its lipogenic effect. Since insulin-metformin combination is commonly used for the treatment of diabetes, it is important to assess the effect of this combined therapy on hepatic steatosis. We evaluated the change in hepatic steatosis following the initiation of insulin and metformin in patients with type 2 diabetes. Methods: Newly diagnosed treatment-naïve patients with type 2 diabetes had their hepatic triglyceride (TG) content measured by magnetic resonance spectroscopy at baseline and after 3 months of treatment with BiAsp 30 insulin, in combination with metformin. Insulin was administered twice daily and titrated to achieve normal capillary blood glucose levels. Metformin was titrated during the first month from 500 mg daily to 1000 mg bid. Results: The average hepatic TG content in 19 enrolled subjects was 11.83±7.61% (range, 0.93-23.16%) and correlated with body mass index (r=.567). Three months of treatment reduced hepatic steatosis by 45%, with 75% of the study subjects achieving a normal level. The change in hepatic TG content was partially explained by changes in HbA1c (P=.006) and cholesterol (P=.003) levels. Conclusions: The combined treatment with insulin and metformin significantly reduced hepatic steatosis in patients with newly diagnosed type 2 diabetes.

KW - Hepatic steatosis

KW - Insulin treatment

KW - Metformin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=34247593406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247593406&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2007.02.005

DO - 10.1016/j.jdiacomp.2007.02.005

M3 - Article

C2 - 17493545

AN - SCOPUS:34247593406

VL - 21

SP - 137

EP - 142

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 3

ER -